title: Systematic review of systemic therapy for advanced or recurrent endometrial cancer.
abstract: OBJECTIVE
  To evaluate the chemotherapeutic options for women with advanced or recurrent endometrial cancer.
  
  
  METHODS
  The MEDLINE, CANCERLIT and the Cochrane Library databases were searched from 1984 to March 2005 for randomized controlled trials (RCTs) comparing chemotherapy regimens in patients with advanced or recurrent endometrial cancer. Studies were included only if patients had measurable or evaluable disease, and/or response rates were reported.
  
  
  RESULTS
  Seventeen RCTs compared regimens involving chemotherapy and/or hormonal therapies. Three chemotherapy trials demonstrated a statistically significant difference in response rates between treatment arms, but only one of these trials showed a modest survival advantage. The addition of cisplatin to doxorubicin in two RCTs significantly improved response rates (1.7- to 2.5-fold higher) but did not impact on survival. In two other RCTs using cisplatin and doxorubicin as standard therapy, the addition of paclitaxel improved response rates (57% versus 34%) and median survival (15.3 versus 12.3 months) when combined with cisplatin and doxorubicin but not when combined with doxorubicin only. Toxicity was increased with the three-drug combination. Quality of life was assessed in one trial, which is currently only in abstract form. Medroxyprogesterone acetate (200 mg/day) was effective in one RCT, particularly in patients with well-differentiated, receptor-positive tumors.
  
  
  CONCLUSIONS
  Combination chemotherapy with doxorubicin and cisplatin results in higher response rates than doxorubicin alone. The addition of paclitaxel to either of these regimens resulted in a small survival advantage in one trial using all three drugs. In light of the limited survival advantage associated with this regimen, the use of less toxic combinations of taxanes with carboplatin requires further study. Medroxyprogesterone acetate is useful in selected patients.
authors.affiliation: London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Carey
authors.forename: Christine
authors.initials: C
authors.lastname: Gawlik
authors.forename: Michael
authors.initials: M
authors.lastname: Fung-Kee-Fung
authors.forename: Alexandra
authors.initials: A
authors.lastname: Chambers
authors.forename: Tom
authors.initials: T
authors.lastname: Oliver
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D004317:Doxorubicin; D017258:Medroxyprogesterone Acetate; D002945:Cisplatin